⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4501241 | 0.79 | MEN1 (0.36) | — | |
| SCHEMBL3676147 | 0.76 | CYP2A6 (0.37) | — | |
| SCHEMBL2986012 | 0.74 | — | — | |
| SCHEMBL8747072 | 0.74 | — | — | |
| SCHEMBL12917335 | 0.74 | SLC6A4 (0.43) | — | |
| SCHEMBL725380 | 0.72 | — | — | |
| SCHEMBL12917337 | 0.70 | — | — | |
| SCHEMBL2034915 | 0.70 | — | — | |
| SCHEMBL14448598 | 0.70 | — | — | |
| SCHEMBL1548500 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9777015-B2 | Useful thiophene derivatives in the treatment of diabetes | METABRAIN RESEARCH (FR) | 2017-10-03 | — | — | US | disclosed |
| US-9777015-B2 | Useful thiophene derivatives in the treatment of diabetes | METABRAIN RESEARCH (FR) | 2017-10-03 | — | — | US | disclosed |
| EP-2875010-B1 | THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | METABRAIN RES (FR) | 2016-08-31 | — | — | EP | disclosed |
| EP-2875010-B1 | THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | METABRAIN RES (FR) | 2016-08-31 | — | — | EP | disclosed |
| US-20150197530-A1 | USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES | METABRAIN RESEARCH (FR) | 2015-07-16 | — | — | US | disclosed |
| US-20150197530-A1 | USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES | METABRAIN RESEARCH (FR) | 2015-07-16 | — | — | US | disclosed |
| EP-2875010-A1 | THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES | Metabrain Research (FR) | 2015-05-27 | — | — | EP | disclosed |
| WO-2014013181-A1 | THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES | METABRAIN RESEARCH (FR) | 2014-01-23 | — | — | WO | disclosed |
| EP-1831207-B1 | AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | disclosed |
| CN-101115749-B | Aminopyrimidine compounds and methods of use | AMGEN INC | 2011-06-22 | — | — | CN | disclosed |
| US-7858785-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7786132-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-01-14 | — | — | US | disclosed |
| CN-101115749-A | Aminopyrimidine compounds and methods of use | AMGEN INC (US) | 2008-01-30 | — | — | CN | disclosed |
| EP-1831207-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | AMGEN, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| WO-2006066172-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-06-22 | — | — | WO | disclosed |